Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$14.66 -2.3%	$11.38	$8.24 ▼ $18.38	$920.43M	1.5	350,432 shs	1.69 million shs
NRIX Nurix Therapeutics	$12.15 -3.2%	$16.48	$11.90 ▼ $29.56	$922.03M	2.18	898,481 shs	623,319 shs
TSVT 2seventy bio	$4.95	$3.24	$2.29 ▼ $5.99	$255.36M	1.73	610,286 shs	445,240 shs
VIR Vir Biotechnology	$6.70 +0.4%	$8.87	$6.40 ▼ $14.45	$918.86M	1.17	1.31 million shs	717,714 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	-7.12%	-10.34%	+71.23%	+17.00%	+17.37%
NRIX Nurix Therapeutics	-1.41%	-9.52%	-23.80%	-34.33%	-13.69%
TSVT 2seventy bio	-0.20%	0.00%	+88.93%	+62.30%	-7.99%
VIR Vir Biotechnology	+1.21%	-2.91%	-26.70%	-10.71%	-33.96%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	3.1007 of 5 stars	3.5	2.0	3.3	5.0	0.0
NRIX Nurix Therapeutics	2.0264 of 5 stars	4.4	0.0	2.8	0.8	0.0
TSVT 2seventy bio	2.9452 of 5 stars	3.2	4.0	1.6	2.5	1.3
VIR Vir Biotechnology	3.555 of 5 stars	4.4	2.0	1.6	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	3.00	Buy	$27.00	84.17% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.88	154.18% Upside
TSVT 2seventy bio	2.38	Hold	$6.67	34.68% Upside
VIR Vir Biotechnology	2.83	Moderate Buy	$35.67	432.34% Upside

Current Analyst Ratings Breakdown

Latest TSVT, MLYS, NRIX, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/17/2025	NRIX Nurix Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/17/2025	NRIX Nurix Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$16.00
3/14/2025	TSVT 2seventy bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
3/11/2025	TSVT 2seventy bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/11/2025	TSVT 2seventy bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$9.00 ➝ $5.00
3/10/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/7/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
2/28/2025	VIR Vir Biotechnology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $31.00
2/28/2025	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $110.00
2/27/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NRIX Nurix Therapeutics	$54.55M	16.90	N/A	N/A	$7.44 per share	1.63
TSVT 2seventy bio	$45.62M	5.60	N/A	N/A	$5.04 per share	0.98
VIR Vir Biotechnology	$63.71M	14.42	N/A	N/A	$11.82 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.64	N/A	N/A	N/A	N/A	-67.97%	-62.40%	5/8/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.89	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	4/9/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$1.12	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	5/1/2025 (Estimated)
VIR Vir Biotechnology	-$615.06M	-$3.82	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	5/1/2025 (Estimated)

Latest TSVT, MLYS, NRIX, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/9/2025	N/A	NRIX Nurix Therapeutics	-$0.72	N/A	N/A	N/A	$12.78 million	N/A
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million
2/12/2025	Q4 2024	MLYS Mineralys Therapeutics	-$1.00	-$0.98	+$0.02	-$0.98	N/A	N/A
1/28/2025	Q4 2024	NRIX Nurix Therapeutics	-$0.67	-$0.75	-$0.08	-$0.75	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	14.02	14.02
NRIX Nurix Therapeutics	N/A	6.46	6.46
TSVT 2seventy bio	N/A	4.95	4.95
VIR Vir Biotechnology	N/A	8.94	8.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
NRIX Nurix Therapeutics	N/A
TSVT 2seventy bio	93.90%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	33.24%
NRIX Nurix Therapeutics	7.20%
TSVT 2seventy bio	7.20%
VIR Vir Biotechnology	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	62.79 million	33.27 million	Optionable
NRIX Nurix Therapeutics	300	75.89 million	70.42 million	Optionable
TSVT 2seventy bio	440	51.59 million	47.87 million	Optionable
VIR Vir Biotechnology	580	137.14 million	116.24 million	Optionable

TSVT, MLYS, NRIX, and VIR Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

March 28 at 5:03 PM | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Time to Sell?

March 27 at 3:52 PM | marketbeat.com

49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.

March 27 at 4:31 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.

March 23, 2025 | marketbeat.com

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 21, 2025 | prnewswire.com

51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital Ltd

March 19, 2025 | marketbeat.com

Bank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

March 19, 2025 | marketbeat.com

Vir enrols first subject in Phase III programme to assess CHD therapy

March 14, 2025 | finance.yahoo.com

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025 | pipelinereview.com

Vir Biotechnology enrolls first patient in ECLIPSE program

March 13, 2025 | markets.businessinsider.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund

March 5, 2025 | marketbeat.com

Hepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&D

March 4, 2025 | theglobeandmail.com

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology

March 4, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

March 4, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Time to Sell?

March 3, 2025 | marketbeat.com

What is HC Wainwright's Forecast for VIR Q1 Earnings?

March 3, 2025 | marketbeat.com

489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.

March 2, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $31.00 at Barclays

March 1, 2025 | marketbeat.com

Vir Biotechnology's (VIR) Buy Rating Reaffirmed at HC Wainwright

March 1, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 8.4% on Insider Selling

February 28, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in Stock

February 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSVT, MLYS, NRIX, and VIR Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$14.66 -0.34 (-2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$14.86 +0.20 (+1.36%)

As of 05:59 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Nurix Therapeutics NASDAQ:NRIX

$12.15 -0.40 (-3.19%)

Closing price 04:00 PM Eastern

Extended Trading

$12.14 -0.01 (-0.04%)

As of 04:20 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

2seventy bio NASDAQ:TSVT

$4.95 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$4.93 -0.02 (-0.30%)

As of 07:01 PM Eastern

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Vir Biotechnology NASDAQ:VIR

$6.70 +0.03 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$6.74 +0.04 (+0.60%)

As of 07:23 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time